-
- YOSHIMOTO Takanobu
- Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School
-
- HIRATA Yukio
- Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School
この論文をさがす
抄録
The pathophysiological role of aldosterone in the development of cardiovascular disease has long been considered to be due its potent volume expansion/hypertensive effect mainly via mineralocorticoid receptor (MR) expressed in renal tubular epithelial cells. However, recent accumulating lines of evidence from clinical and experimental studies have suggested that direct cardiovascular effect of aldosterone contributes to the development of cardiovascular injury via MRs in non-epithelial tissue. A series of recent clinical studies have revealed that patients with primary aldosteronism have higher incidence of cardiovascular and renal complications than those with essential hypertension, and that aldosterone antagonism has cardiovascular protective effect in patients with heart failure independent from blood pressure. Numerous experimental studies have shown that both inflammation and oxidative stress play an initial and key role in the development of aldosterone-induced cardiovascular injury via non-epithelial MR activation. In this review, we discuss recent research progress in aldosterone and MR effects, with special emphasis on the pathophysiological role of aldosterone in cardiovascular diseases and the possible molecular mechanism(s) of cardiovascular injury by non-epithelial MR activation.<br>
収録刊行物
-
- Endocrine Journal
-
Endocrine Journal 54 (3), 359-370, 2007
一般社団法人 日本内分泌学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001206300614144
-
- NII論文ID
- 80018411408
- 130004770030
-
- ISSN
- 13484540
- 09188959
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可